Loading
Tampa-based Oragenics appointed Bruce Cassidy and John Gandolfo to its board of directors, the company says.
Oragenics is a development-stage company focused on nasal delivery of pharmaceutical medications including drugs involving neurological treatment, and drugs fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of coronavirus.
The Oragenics chairman says the pair will complement the board and company.
Subscribe today. Cancel anytime.
Your free article limit has been reached this month.
Subscribe now for unlimited digital access to our award-winning business news.
Join thousands of executives who rely on us for insights spanning Tampa Bay to Naples.
